What Is a Tumour Board — And Was Your Case Discussed?

A tumour board is a scheduled meeting where doctors from several specialties review one patient’s case together and agree a plan. Pathology, imaging, stage and treatment options are discussed at the same table. The output is a documented recommendation from a group, not a decision taken by one doctor alone.

In most Indian centres the same meeting is called a multidisciplinary team meeting, or simply the MDT. The name matters less than the structure. A board exists so that the person who read your biopsy, the person who read your scan and the people who would treat you are all looking at the same case on the same day. NCCN and ESMO both describe multidisciplinary review as standard practice in planning cancer treatment rather than an optional refinement.

If only one specialty is in the room, it is a clinic, not a board. That is worth knowing before you choose where to be treated — How to Choose a Centre for Immunotherapy sets out where multidisciplinary review sits among the other things a centre has to be able to do.

Ask, and ask for it in writing. A case that has been through a tumour board leaves a dated record: the date of the meeting, the specialties present, the conclusion, and any test still awaited. If nobody can produce that record, the discussion was informal or did not happen.

This is not an accusation and should not be delivered as one. Plenty of sound decisions begin with two doctors talking in a corridor, and a corridor conversation is not negligence. But it is not a board either, and it does not travel. If you move city, change centre, or land in a casualty department at midnight, the only version of that discussion that helps you is the one written down. Ask for these five things:

• The date of the meeting. A conclusion reached before your biomarker report arrived may no longer be the current plan.
• Which specialties were present. Individual names are not essential. Pathology, imaging and at least two treating specialties are.
• The conclusion, in one or two sentences, in your file. Not a summary given verbally in the clinic and then lost.
• What was considered and set aside, and why. The discarded options are often more informative than the chosen one.
• What is still pending. A biomarker result, a repeat biopsy, a PET-CT slot. A plan waiting on a report is not yet a plan.

If you are being asked to sign anything before that conclusion exists in writing, slow down. Understanding Your Immunotherapy Consent Form covers what the form you are handed actually commits you to, and what should already be settled before it reaches you.

Yes. Any patient or family can ask for a multidisciplinary review, and a reasonable team will arrange it. It is a routine request, not a complaint and not a challenge to your doctor. Ask early, ask in writing, and ask what the board needs before it can discuss your case.

1. 1

   Ask it in the room

   Say it plainly: “Can my case be discussed at the tumour board?” Asked before treatment starts, it is a normal question with a normal answer.

2. 2

   Put the request in writing

   One line in an email or a note to the clinic is enough. Written requests get scheduled; verbal ones get remembered differently by everyone.

3. 3

   Gather the material

   Pathology report with blocks or slides, all imaging on a disc rather than as printed films, blood results, and any biomarker testing already sent.

4. 4

   Ask what is still missing

   Biomarker testing takes days to come back. A board cannot settle eligibility on a report that has not arrived, so find out what is being waited for.

5. 5

   Ask when the board sits

   Many centres meet weekly. Ask for the date, so you are waiting for something specific instead of waiting blind.

6. 6

   Ask for the conclusion on paper

   Take a copy home. It is the document that tells any other doctor what was already considered, so nothing has to be repeated from scratch.

If a scan is requested to complete the picture, remember that staging and response-assessment PET-CT is coordinated at partner imaging centres rather than done in-house, so the appointment date and any travel time quoted to you are indicative only. Build a little slack into the plan. Questions to Ask a Centre Before Starting Immunotherapy lists the rest of what is worth settling in the same conversation.

It changes who checks the plan. A board re-reads the pathology, confirms the stage, reviews biomarker results and raises options a single specialty may not. In a proportion of cases the recommendation changes. NCCN and ESMO describe multidisciplinary review as standard practice in cancer care, not an optional extra.

• The pathology is read again. Subtype, grade and receptor or biomarker reporting are checked by the pathologist against the slides, not simply copied from the report header.
• The stage is tested against the images. A radiologist looking at the scan can reach a different conclusion from the one summarised in the text of a report.
• The order of treatment gets questioned. Surgery first or drug treatment first is a genuine decision, and it is answered differently depending on who is asked.
• Something outside one specialty’s habit gets raised. A referral, a supportive-care need, a trial worth asking about, or a test nobody had ordered yet.
• Fitness and other illnesses are weighed. Diabetes, kidney function, an autoimmune condition or a heart problem can change what is safe long before it changes what is possible.

None of this predicts how one particular patient will respond to treatment. What it does is reduce the chance that the plan was built on an unchecked assumption — a different kind of benefit, and a real one.

Because immunotherapy eligibility is decided on paper before it is decided in a clinic. PD-L1 scoring, MSI or mismatch-repair status, the approved indication, autoimmune history and baseline steroid use all have to be read together. A board is where a pathologist and an oncologist settle those questions in one sitting.

If cell therapy comes up. CION Cancer Clinics does not provide CAR-T or any other cell therapy, and does not stock CAR-T product. If a board or a treating team raises it as an option, the correct next step is a referral to a licensed cell-therapy centre with apheresis, cell processing and intensive-care capability — not a search for a unit willing to attempt it locally.

It cannot promise a result. A board improves the process by which your plan is made; it does not change how any individual will respond to treatment. It cannot create eligibility the pathology does not support, it does not replace your consent, and it cannot arrange treatment the centre does not provide.

• It is not a prediction about you. A well-run discussion makes a considered plan more likely. It says nothing about what will happen in your particular case.
• It does not replace consent. A recommendation is an offer. You still decide, and you are entitled to the risks and the alternatives in language you understand before you sign.
• It cannot invent eligibility. Sometimes the conclusion is that immunotherapy is not appropriate for this cancer, this stage or this patient. That is a real answer, and a useful one.
• It cannot deliver what the centre does not have. Where the right treatment sits elsewhere — cell therapy above all — the board’s job is to say so and refer, not to improvise.
• It does not remove your right to a second opinion. A board is several specialties inside one institution. A second opinion is a different institution. Having both is normal.

Three questions usually sit alongside this one: whether the centre you are considering can deliver and monitor the plan, what to ask before you commit to it, and what the consent form you will be handed actually says. These pages take each in turn.

• How to Choose a Centre for Immunotherapy — what a centre must be able to do beyond running the infusion, with multidisciplinary review as one item on the list.
• Questions to Ask a Centre Before Starting Immunotherapy — the questions worth asking once, in the first consultation, while everything is still open.
• Understanding Your Immunotherapy Consent Form — what you are agreeing to, what should already be decided before it is put in front of you, and what to ask before signing.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring and escalation fit together as one pathway.

One last thing worth saying plainly: not starting immunotherapy is a legitimate outcome of a board discussion, and so is being treated somewhere other than here. If the conclusion points away from this treatment or away from this centre, that belongs in the conversation with your oncologist before the first cycle — not in a decision made quietly, halfway through.

Get the Board’s Conclusion in Writing

Bring your reports and imaging. We will set out what was considered, what was recommended, and what is still pending — on paper, so it travels with you.